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Summary The effect of folic acid supplements on 6-mercaptopurine remission maintenance therapy in
lymphoblastic leukaemia (ALL) was investigated in a retrospective longitudinal study of 10 children. Red cell
concentrations of 6-thioguanine nucleotide, a cytotoxic metabolite of 6-mercaptopurine, were measured and
the peripheral neutrophil count was used as an index of myelosuppression. During the control period of the
study there were significant correlations between 6-mercaptopurine dose and 6-thioguanine nucleotide
concentration (rs=0.59, P<0.0005) and between 6-thioguanine nucleotide concentration and the peripheral
neutrophil count at 14 days (r, = -0.58, P<0.0005). These relationships were absent when the same children
were subsequently taking folate supplements. Also when taking folate supplements the children tolerated
significantly more 6-mercaptopurine (P<0.005) for a significantly longer time (P<0.005) before neutropenia
developed. There was no significant difference in red cell 6-thioguanine nucleotide concentration in the
absence and presence of folate supplements. These findings suggest that folate supplements may interfere with
remission maintenance therapy in ALL.
Folic acid has a fundamental role in the growth
and reproduction of cells (Woods, 1964; Erbe &
Wang, 1984). It is specifically concerned with
biochemical reactions involving the transfer and
utilisation of the single carbon moiety. These
reactions are essential in the synthesis of purines
and thymine, the methylated pyrimidine of DNA.
Blood cells are subject to a relatively rapid rate of
synthesis and destruction; interference with their
formation is an early sign of folic acid deficiency.
Inchildhoodleukaemiaoral remission maintenance
chemotherapy with 6-mercaptopurine and metho-
trexate is titrated against its effect on the white
blood cell count. This effect is exaggerated when
cryptic or overt folate deficiency is present
(Herbert, 1962) For this reason folate supplements
are sometimes given routinely to leukaemic children
to avoid reduction or withdrawal of drugs. They
are given in the general belief that they do not
influence the anti-leukaemic effect but avoid some
of the treatment-associated morbidity.
6-Mercaptopurine is universally used in the
treatment of childhood leukaemia to prolong the
duration of remission induced with other drugs. Its
precise mode of action is uncertain but cyto-
toxicity can be related to the incorporation of
6-mercaptopurine derived 6-thioguanine nucleotide
into DNA (Tidd & Paterson, 1974). Our investiga-
tions of 6-mercaptopurine metabolism in childhood
lymphoblastic leukaemia, based on the assay of
its active intracellular metabolite 6-thioguanine
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nucleotide (Herber et al., 1982; Lennard et al.,
1983) have shown that red cell 6-thioguanine
nucleotide concentrations can be related to
subsequent neutropenia. Red cell 6-thioguanine
nucleotide concentrations are not statistically
related to the peripheral neutrophil count at the
time of sampling or seven days later but to the
neutrophil count 14 days later; an effect compatible
with a cytotoxic action on bone marrow stem cells.
The aim of this study was to investigate the effect
of folic acid supplements on 6-mercaptopurine
therapy in childhood lymphoblastic leukaemia
(ALL).
Patients and methods
Ten unselected consecutive children remaining in
remission from ALL and attending the Sheffield
Children's Hospital were studied between
September 1982 and Novqmber 1983. All were on
the Medical Research Council therapeutic trial
UKALL VIII and had been in complete remission
for at least 33 weeks. Remission maintenance
therapy consisted of daily 6-mercaptopurine and
weekly methotrexate, both oral, at starting doses of
75 and 20mgm 2 respectively. Both doses were
reduced to 75%, 50% and 0% of the starting dose
in response to neutropenia or thrombocytopenia at
the time of prescription. Monthly pulses of a single
dose of intravenous vincristine (1.5mgm 2) and
five doses of oral prednisone (40mgm-2) were
given to all patients irrespective of blood counts.
6-Mercaptopurine metabolism was investigated in
a retrospective longitudinal study of the 10 children
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(6 girls and 4 boys) aged between 2 and 15 years.
The children were studied for a 12 week period
when not taking folate supplements and not overtly
folate deficient (=control period) and again later
over a 12 week period when taking folate
supplements (folic acid, 5mg/day). The time on
remission maintenance therapy varied from 8 to 11
months and 18 to 30 months for the control and
folate supplements periods respectively. No child
was taking concurrent cotrimoxazole therapy or
suffering from any obvious viral infections at the
time of the study.
Blood samples (0.5 ml) for the assay of red cell 6-
thioguanine nucleotide (Lennard & Maddocks,
1983) were obtained at the end of each month
at the time of venepuncture for vincristine
administration. Intracellular concentrations of 6-
thioguanine nucleotide were compared to drug dose
and subsequent neutrophil count during the control
and folate supplements.
Red cell folate concentrations were measured by
isotope dilution ('SumulTRAC' diagnostic kit,
Becton Dickinson). Folate concentrations were not
measured on a routine basis and were therefore not
available for every child.
The absolute neutrophil count was used as an
index of myelosuppression and measured in routine
blood counts at 14 day intervals from the start of
the study. Neutropenia was defined as a reduction
in the absolute neutrophil count below 1.5 x 1091-l '.
Statistical comparisons were made using the
Wilcoxon matched pairs signed-ranks test.
Correlations were assessed by the Spearman rank
correlation coefficient (rj).
Table I The effect of folate supplements on the
relationships between 6-mercaptopurine (6MP) daily dose
(mgm-2), 6-thioguanine nucleotide (6TGN) concentration
(pmol/8 x 108 red blood cells) and absolute neutrophil
count (ANC x 1091-')
Folate supplements
Without With
6 MP dose r, 0.59 -0.16
vs. n 30 30
6TGN concentration P <0.0005 NS
6MP dose r, 0.26 0.01
vs n 30 30
ANC at 14 days P NS NS
6TGN concentration r, -0.58 -0.22
vs. n 30 28
ANC at 14 days P <0.0005 NS
6TGN concentrations were determined at monthly
intervals throughout the study periods, each child having
three measurements. All the data collected were used, no
attempt was made to select datum points.
Results
Correlations
The effect of folate supplements on the relationship
between 6-mercaptopurine dose, 6-thioguanine
nucleotide concentration and the absolute
neutrophil count at 14 days are summarised in
Table I.
A significant positive correlation between 6-
mercaptopurine dose and red cell 6-thioguanine
nucleotide concentration and a significant negative
correlation between red cell 6-thioguanine nucleotide
concentration and the absolute neutrophil count
at 14 days were observed during the control period.
The relationships observed during the control
period of the study were absent during the folate
supplements period (Figures 1 and 2).
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Figure I The relationsilips betw een 6-mercaptopurine
(6MP) daily dose and red blood cell (RBC) 6-
thioguanine nucleotide (6TGN) concentration during
the control (a) and folate (b) supplement periods of
the longitudinal study. Control: r.,=0.59; n=30;
P<0.0005 Folate: r, = -0.16; n=30; P=NS.
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counts determined were significantly higher than
during the control period. Comparison of 6-
thioguanine nucleotide concentrations showed no
statistical difference between the control and folate
supplements periods.
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Figure 3 When receiving folate supplements the 10
children studied required significantly more 6-
mercaptopurine (6MP) (P<0.005) to produce
neutropenia. Four children (V) did not achieve
neutropenia whilst taking folate supplements. ([l)
control; (E) folate.
Patient
Figure 4 When receiving folate supplements the 10
children studied took a significantly longer time
(P<0.005) to achieve neutropenia. Four children (V)
did not achieve neutropenia during the study period.
([l) control; ([) folate.
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Figure 2 The relationship between red blood cell
(RBC) 6-thioguanine nucleotide (6TGN) concentration
and the absolute neutrophil count (ANC) 14 days later
during the control (a) and folate (b) supplement
periods of the longitudinal study. Control: r,= -0.58;
n=30; P<0.0005. Folate: r,= -0.22; n=28; P=NS.
Comparisons
The total dose of 6-mercaptopurine tolerated prior
to the occurrence of neutropenia during the control
and folate supplements periods was compared
(Figure 3). When receiving folate supplements the
10 children tolerated significantly more 6-
mercaptopurine (P<0.005) for a significantly
longer time (P<0.005, Figure 4) before neutropenia
developed.
The total monthly 6-mercaptopurine dose, 6-
thioguanine nucleotide concentrations and absolute
neutrophil counts determined during the control
and folate supplements periods of the longitudinal
study are summarised in Table II. When taking
folate supplements the total monthly 6-
mercaLptopurine dose and absolute neutrophil
Folate status
Control period Prior to the control period red cell
folate concentrations were determined in four
children. The mean red cell folate concentration
was 318 (range 279-412) gI-1. The remaining
children showed no clinical or haematological
evidence of folate deficiency at the start of the
control period.
Folate supplements period Prior to folate supple-
ments seven children had their red cell folate con-
centrations measured. Five children had red cell
folate concentrations below, and two at the lower
end, of the normal range (160-700pgl-1). The
mean red cell folate concentration was 178 (range
106-287),g1-').
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Table II The total monthly 6-mercaptopurine (6MP) dose, 6-thioguanine nucleotide (6TGN)
concentrations and absolute neutrophil counts (ANC) determined during the control and folate
supplement periods of the longitudinal study.
Without With n z P
Monthly 6MP dose Median 1497 1983 30 2.33 =0.01
(mgm-2) Range 327-2134 660-2081
6TGN concentration Median 234 210 30 1.52 NS
(pmol/8 x 108 RBCs) Range 0-958 30-958
ANCs ( x 1091l) Median 1.78 2.3 58 3.1 =0.001
Range 0.11-6.64 0.25-6.0
Discussion
Our investigations into 6-mercaptopurine
metabolism in childhood leukaemia have shown
that intracellular 6-thioguanine nucleotide
concentration is a better index of cytotoxicity than
drug dose, and that the relationship between 6-
thioguanine nucleotide and cytotoxic effect, as
indicated by neutropenia, is improved when other
potentially myelosuppressive influences such as
concurrent cotrimoxazole therapy are excluded
(Rees et al., 1984). The work reported in this paper
indicates that folate supplements may also interfere
with this relationship, which raises the possibility
that they may in turn interfere with the anti-
neoplastic effect of 6-mercaptopurine.
Specifically, when taking folate supplements each
child tolerated significantly more 6-mercaptopurine,
and for a longer time, before developing neutro-
penia. Four of the ten children studied did not
develop neutropenia during the folate supplements
period. The relationships observed between drug
dose and neutrophil count with the intracellular
metabolite 6-thioguanine nucleotide during the
control period was absent when the children were
taking folate supplements. Additionally, during the
12 week folate supplements period significantly
more 6-mercaptopurine was required to produce
the same intracellular concentration of6-thioguanine
nucleotide, the absolute neutrophil cell counts
recorded were also significantly higher.
The reasons for these observations are not clear.
It is possible the increased requirement of 6-
mercaptopurine in the face of folate supplements
could be a pharmacodynamic effect caused by high
intracellular folate concentrations. High folate
concentrations stimulate nucleic acid and de novo
purine synthesis (Walzen et al., 1983), and the
antimetabolite effects of 6-mercaptopurine are due
to its behaviour as a competitive inhibitor in both
the de novo and salvage pathways of purine
metabolism. An increase in the concentrations of
physiological purines, due to stimulated de novo
synthesis, will require an increased concentration of
6-mercaptopurine to produce the same con-
centration of 6-thioguanine nucleotide. Thus the
UKALL VIII protocol, with a ceiling dose of 6-
mercaptopurine at 75mgm2, could be inadequate
for the child taking folate supplements.
Alternatively, the perturbations in 6MP
dose/effect relationships we have seen could at least
in part be secondary to a primary effect of folate
supplements on methotrexate pharmacokinetics.
Folate supplementation may reduce the myelo-
suppressive action of weekly methotrexate or alter
6-mercaptopurine absorption. Both are possible.
The attenuation of methotrexate enterotoxicity by
folate supplements could influence the passive,
membrane-limited absorption of 6-mercaptopurine
(Ravis et al., 1984). Biotransformation, by the
enzyme xanthine oxidase, to the inactive metabolite
6-thiouric acid, occurs predominantly in the brush
order area of the columnar epithelial cells of the
small intestine (Berlin & Hawkins, 1968).
Another point to be considered is that the
control period preceded the folate supplements
period of the study, and it is possible that merely
the duration of treatment could influence 6-
mercaptopurine metabolism. We do not think this
is likely, however, as we have previously
investigated children according to the duration of
maintenance (Herber et al., 1982; Rees et al., 1984)
and found no change in the strength of 6-
thioguanine nucleotide relationships with 6-
mercaptopurine dose or the absolute neutrophil
count at 14 days with the passage of time.
Whatever the explanation for our findings, we
can conclude that the dose/effect relationship with
oral 6-mercaptopurine therapy is disturbed by
folate supplements. It must therefore be assumed
that the antileukaemic effect of the drug may also
be affected.
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